Press Release
Latest data of InnoCare’s Orelabrutinib for the Treatment of SLE Presented at LBA Session of EULAR 2022
06 Jun, 2022
107
3771
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China
26 May, 2022
104
3768
InnoCare Presents Pre-Clinical Data of ICP-723 at AACR Annual Meeting 2022
11 Apr, 2022
108
3727
InnoCare Announces Dosing of First Patient in Clinical Trial of RTK Inhibitor ICP-033 in China
30 Mar, 2022
91
3721
InnoCare to Hold 2022 R&D Day on April 20, 2022
29 Mar, 2022
110
3718
InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China
28 Mar, 2022
128
3703
InnoCare Releases 2021 Annual Results and Business Highlights
23 Mar, 2022
171
3688
InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Waldenström’s Macroglobulinemia in China
14 Mar, 2022
117
3680
InnoCare to Host 2021 Full Year Earnings Call on March 23, 2022
11 Mar, 2022
77
3677
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China
02 Mar, 2022
83
3671